LSD Factory? DEA Eyes Bulk Trip Production License
Published Date: 4/18/2025
Notice
Summary
Restek Corporation wants to become a big-time maker of certain controlled substances, including some strong drugs like LSD and marijuana. People and companies involved can share their thoughts or ask for a hearing by June 17, 2025. This move could impact drug manufacturing rules and how these substances are handled in the future.
Analyzed Economic Effects
2 provisions identified: 1 benefits, 1 costs, 0 mixed.
New bulk manufacturer registration for Schedule I drugs
Restek Corporation applied on February 19, 2025 to be registered to bulk manufacture a list of Schedule I controlled substances (examples include Gamma Hydroxybutyric Acid, Lysergic acid diethylamide (code 7315), Marihuana (code 7360), Tetrahydrocannabinols (code 7370), 3,4-Methylenedioxymethamphetamine (code 7405), Heroin (code 9200), and fentanyl-related codes 9830/9831). The company says it will manufacture these drugs as Drug Enforcement Administration-exempt certified reference materials to provide access to compounds that are difficult to source; interested parties may submit comments or request a hearing by June 17, 2025.
Synthetic-only authorization for marijuana/THC
For drug codes 7360 (Marihuana) and 7370 (Tetrahydrocannabinols), Restek plans to bulk manufacture these drugs as synthetic versions, and the registration expressly authorizes no other activities for these drug codes. This limits Restek's authorized work on those codes to synthetic DEA-exempt certified reference materials.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20757, Schedules of Controlled Substances; Removal of Exemption Status for Inactive Butalbital Products
The DEA is removing the special exemption for certain inactive butalbital prescription products that are no longer made or sold. Starting November 9, 2026, these products won’t be treated as exempt under drug laws anymore, but active products stay the same. This change mainly affects drug companies and pharmacies handling these old products, with no new costs for active medicines.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-06708, Notice of Availability; Service Contract Inventory
The Department of Justice just shared its 2023 list of service contracts over $25,000, showing how they use contractors and federal workers. This helps make sure the right balance is kept and money is spent wisely. If you work with or watch DOJ contracts, this update is your go-to for transparency and smart spending insights.
Next: 2025-06710, Bulk Manufacturer of Controlled Substances Research Triangle Institute
Research Triangle Institute wants to make large amounts of a controlled substance called tetrahydrocannabinols for research and testing. People who already make or use these substances can share their thoughts or ask for a hearing by June 17, 2025. This move helps support scientific studies without changing any other drug activities or costs.